Zetagen Therapeutics to Present Promising Preclinical Data at SABCS: Zeta-BC-007 Demonstrates Superior Tumoricidal Activity and Survival Benefit in Breast Cancer Model
Survival Advantage: Mice treated with Zeta-BC-007 survived beyond 60 days, unlike those receiving Tamoxifen (TAM) or Abemaciclib (ABE) Tumor Reduction: Zeta-BC-007 combinations reduced tumor volume by up to 66%, compared to 34% (TAM) and 15% (ABE) Synergistic
(Financial Post, 2025-11-04T15:50:53Z)